Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by qwerty22on Oct 22, 2021 1:23pm
129 Views
Post# 34038122

RE:RE:RE:RE:New PR aroundVM

RE:RE:RE:RE:New PR aroundVMFour observations from the result that I want to consider together.

1) "When SORT1 expression was repressed through specific siRNA-mediated gene silencing (Figure 4A), MMP-9 was also decreased (Figure 4B). SORT1 silencing lead to decreased 3D structures when compared to scrambled siRNA in ES-2 ovarian cancer cells (Figure 4C) and in MDA-MB-231 TNBC cells"

2) "
After 12 h, increasing concentrations of TH1904 strongly inhibited in vitro VM whereas unconjugated Doxorubicin or Doxil, up to 20 µM, slightly affected VM"

3)"
The unconjugated TH19P01 peptide itself was found not to alter VM (data not shown)"

4)"
Pretreatment of MDA-MB-231 cells (Figure 7A) or ES-2 cells (Figure 7B) cells with TH1902 or TH1904 respectively inhibited cell migration. More importantly, specific silencing of SORT1significantly prevented the anti-migratory effect of both conjugates. It is to note that, in our experimental settings, SORT1 silencing did not alter basal cell migration as specifically assessed through impedance values collected through the xCELLigence"

So 1) says silencing SORT1 stops VM. 2) says PDCs also stop VM. 3) says peptide alone has no effect. 4) say PDC impacts cell migration only in the presence of SORT1 but SORT1 silencing doesn't.
To me that's a super interesting result. There may be technical reasons that explain this based on the way the experiments are performed but if it's explained by the MOA of the various molecules it seems to suggest to me there is something different in the action of the PDC. Cell migration is a necessary part of VM and in this set of expts only the PDC has detectable effects on VM and migration (compared to siRNAvor peptide-alone). To me it says the PDC is doing bonus things. If we thought of this from a business perspective a company company like Sortina (the Swedish guys) are trying to develop a SORT1 inhibitor as potential rival. This set of results suggest potentially the PDCs doing something akin to the silencing and then something a little bit more. Just a sniff of that at the moments.
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse